Erectile dysfunction (ED) may reflect vascular alterations associated with imbalanced matrix metalloproteinases (MMPs) activities. However, no previous study has compared MMPs levels in ED patients with those found in healthy subjects. We measured the circulating MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in ED patients, with or without diabetes mellitus (DM), and in healthy controls. We studied 28 healthy men (control group), 35 men with ED (ED group), and 33 men with ED and DM (ED/DM group). MMP-2, MMP-9, TIMP-1 and TIMP-2 plasma levels were measured by enzyme-linked immunosorbent assay and zymography. We found no differences in MMP-9 levels (P40.05) among groups. However, while patients in the ED group had similar TIMP-1 levels compared with those found in the control group, we found higher TIMP-1 levels and lower MMP-9/ TIMP-1 ratios in the ED/DM group compared with controls (Po0.05). While both groups of patients (ED and ED/DM) had slightly lower MMP-2 levels compared with controls (Po0.05), we found no differences in TIMP-2 levels among the study groups (P40.05), and no differences in MMP-2/TIMP-2 ratios (P40.05). We found evidence indicating lack of significant alterations in circulating net MMP-9 and MMP-2 activities in patients with ED, and lower net MMP-9 activity in diabetic patients with ED.
Introduction
Erectile dysfunction (ED) is a clinical condition affecting millions of men worldwide, and is attributable to different causes including neurological, hormonal, psychological and vascular problems. 1, 2 However, vascular dysfunction has a major role in this condition, and it is now clear that ED may reflect vascular functional and structural alterations found in cardiovascular diseases. [1] [2] [3] Indeed, ED shares many risk factors with cardiovascular diseases [4] [5] [6] [7] and it may be an early manifestation of vascular dysfunction, 8 and possibly a clinical marker for cardiovascular diseases. 2, 9 Moreover, ED is very common among men with diabetes mellitus (DM), [4] [5] [6] 10, 11 in whom the prevalence has been reported to vary from 20-71%. 10 Recent studies have implicated matrix metalloproteinases (MMPs) as key players in the functional and structural cardiovascular alterations associated with hypertension [12] [13] [14] [15] and with other cardiovascular diseases. 16, 17 Although MMPs are widely known to degrade the components of the extracellular matrix, they also have many other roles that are now being widely studied, especially in the cardiovascular system. 17, 18 However, although imbalanced MMPs activities may underlie the vascular alterations of many cardiovascular diseases, there is no study examining the hypothesis that patients with ED have imbalanced levels of MMPs. In addition, while there is evidence showing increased MMPs levels in DM, 19 there is no study comparing MMPs levels in diabetic and nondiabetic patients with ED.
In the present study, we hypothesized that altered MMPs concentrations would be found in patients with ED, especially in patients with ED and DM, compared with healthy controls. Therefore, we studied the circulating MMP-2 and MMP-9 levels (which are the very relevant MMPs in the pathogenesis of cardiovascular diseases [12] [13] [14] [15] [16] [17] [18] ) in ED patients with or without DM, and in healthy controls. In addition, we have also assessed the circulating levels of major MMPs endogenous inhibitors, the tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP-2. In fact, MMP-9/TIMP-1 and MMP-2/ TIMP-2 ratios may provide improved information regarding circulating net MMP-9 and MMP-2 activities.
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Materials and methods
Subjects
This study was approved by our Institutional Human Research Ethics Committee, and each subject provided written informed consent. A total of 68 ED patients were recruited from our Urology outpatient clinic. These patients were divided into two groups: diabetic ED and nondiabetic ED (ED/DM and ED; N ¼ 33 and 35, respectively) groups. All the subjects provided a complete health history, and underwent a physical examination and laboratory analysis. The patients in the ED and ED/DM groups were selected after medical diagnosis of organic ED and erectile function evaluated with basis on the International Index for Erectile Function (IIEF) score o26. 22, 23 Only patients with type 2 DM were included. Patients with anatomical abnormalities, Peyronie's disease, penile implants, premature ejaculation, hypogonadism, hypothyroidism, or any other endocrine or neurological disorders were not included in the present study. Moreover, patients with post-prostatectomy ED were also excluded from the present study. As a control group, we studied 28 healthy subjects, which had no signs or symptoms of any disease condition and were recruited from the general public. These subjects were included if their IIEF were X26.
Laboratory analyses
Serum lipid profile (total cholesterol, triglycerides and high-density lipoprotein cholesterol), glucose, urea and creatinine concentrations were measured with commercially available kits using standardized techniques (Labtest, Lagoa Santa, MG, Brazil). Lowdensity lipoprotein concentration was calculated according to the Friedewald's formula.
Measurement of plasma MMP-9, MMP-2, TIMP-1 and TIMP-2 Venous blood samples from each subject were collected into ethylenediaminetetraacetic acid vaccutainer tubes (Becton-Dickinson, Sao Paulo, Brazil) by venipuncture. The blood samples were centrifuged at 2000 Â g for 10 min, and plasma fractions were stored at À70 1C until used for biochemical measurements.
The plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were measured with commercially available DuoSet s enzyme-linked immunosorbent assays kits (R&D Systems, Minneapolis, MN, USA), according to manufacturer's instructions. According to the manufacturer, the MMP-9 DuoSet s kit allows the measurement of active (82 KDa) and pro (92 KDa) forms of MMP-9, but not the 65 KDa form. This assay also recognizes MMP-9 complexed with lipocalin-2/NGAL. The other kits exhibited no cross-reactivity or interference.
SDS-PAGE gelatin zymography of MMP-9 and MMP-2
Gelatin zymography of MMP-9 and MMP-2 from plasma samples was performed as previously described. 24, 25 Briefly, plasma samples were separated by electrophoresis on 7% SDS-PAGE copolymerized with gelatin (1%) as substrate. After electrophoresis was complete, the gel was incubated for 1 h at room temperature in a 2% Triton X-100 solution, and incubated at 37 1C for 16 h in Tris-HCl buffer, pH 7.4, containing 10-mmol l À1 CaCl 2 . Afterwards, gels were stained with 0.05% coomassie brilliant blue G-250, and then destained with a solution with 30% methanol and 10% acetic acid. Gelatinolytic activity was detected as unstained bands against a bluestained background. Enzyme activity was assayed by densitometry using ImageJ Program (National Institutes of Health, USA). MMP-2 and MMP-9 were identified as 72 and 92 KDa bands, respectively, by direct comparison with relative mobility of Sigma (St Louis, MO, USA) SDS-PAGE LMW marker proteins.
Statistical analysis
Clinical characteristics and biochemical parameters of the studied groups were compared by one-way ANOVA followed by the Dunnett multiple comparisons test (parametric data), by Kruskall-Wallis test followed by Dunn's multiple comparison test (nonparametric data) or by w 2 test. The results were expressed as mean ± s.d. or shown as dot plots. Po0.05 was considered the minimum level of statistical significance.
Results
Clinical and laboratorial characteristics of studied subjects are presented in Table 1 . We found no significant differences in age, ethnicity, body mass index, % physical exercise practitioners, systolic arterial pressure, diastolic arterial pressure, highdensity lipoprotein, low-density lipoprotein, total cholesterol, triglycerides, urea and creatinine among the study groups (P40.05; Table 1 ). However, as MMPs in erectile dysfunction JJ Muniz et al expected, patients in the ED and ED/DM groups had lower IIEF scores when compared with those found in the control group (Po0.05; Table 1 ), and diabetic patients had higher fasting glucose levels than non diabetics (Po0.05; Table 1 ). The average duration of diabetes in ED/DM group was B11, varying from 6 to 20 years.
A representative zymogram of plasma samples is shown in Figure 1a . Gelatin zymography of plasma samples showed all forms of MMPs usually found in human plasma, including the 225 KDa MMP-9 homodimer, the 130 KDa complex of MMP-9 with neutrophil lipocalin, the 92 KDa MMP-9 and the 72 KDa MMP-2 ( Figure 1a) . Gelatinolytic activity was completely inhibited by 5 mM ethylenediaminetetraacetic acid or 1 mmol l À1 1, 10-phenantroline (data not shown), thus confirming that these bands correspond to MMP activity. In addition, we have also found bands between the 92 and the 72 KDa, which were not inhibited by phenantroline and correspond to non-MMP gelatinases. 26 We found no significant differences in MMP-9 levels measured by both zymography and enzymelinked immunosorbent assay (P40.05; Figures 1b  and c, respectively) among the study groups. However, while patients in the ED group had similar TIMP-1 levels compared with those found in the control group, we found slightly higher TIMP-1 levels, and therefore lower MMP-9/TIMP-1 ratios in the ED/DM group compared with controls (Po0.05; Figures 1d and 1e, respectively) .
While both groups of patients (ED and ED/DM) had slightly lower MMP-2 levels compared with the control group (Po0.05; Figure 2a ), we found no significant differences in TIMP-2 levels among the study groups (P40.05; Figure 2b) , and no significant differences in MMP-2/TIMP-2 ratios (P40.05; Figure 2c ).
Discussion
This is the first study to assess the circulating MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with ED. In contrast with our hypothesis, we found no increases in MMPs or in net MMPs activities in ED patients, although we found slightly increased TIMP-1 levels in diabetic patients with ED and decreased MMP-2 in both groups with ED.
Imbalanced MMPs activities have been implicated in many clinical cardiovascular diseases, [12] [13] [14] [15] [16] [17] [18] 27 and the use of MMPs inhibitors has been suggested as a relevant pharmacological target, especially to prevent the vascular alterations associated with these conditions. 12, 13, [28] [29] [30] While there is evidence that MMPs in erectile dysfunction JJ Muniz et al patients with ED are more likely to have the vascular alterations commonly found in cardiovascular diseases, 2,4-9 especially among diabetics, 4-6,10,11 our findings showed similar net MMP-2 and MMP-9 activities in ED patients and in healthy controls, thus suggesting that these enzymes may not be involved in ED. Importantly, MMPs levels were carefully assessed by two independent, different techniques in the present study, thus minimizing the probability of analytical limitations. Moreover, the lack of significant differences in TIMPs levels when ED patients were compared with healthy controls gives further support for the lack of major differences between these groups in net MMPs activities. However, some caution is necessary when interpreting these data. Although it is reasonable to believe that MMPs/TIMPs ratios may reflect net MMPs activities, this idea may be too simplistic.
To our knowledge, there is no other study examining the circulating MMPs levels in ED, irrespective of the underlying etiology for ED. While a number of factors may contribute to ED, DM has been identified as a major risk factor for ED. 11 However, notwithstanding the fact that DM has been associated with altered MMPs and TIMPs levels, 19 we found only slightly higher TIMP-1 levels in the ED/DM group compared with healthy. It is highly probable that this minor difference may be due to DM, and not to ED itself. This suggestion is MMPs in erectile dysfunction JJ Muniz et al supported by previous findings showing higher TIMP-1 levels in DM, 19 and to the lack of significant differences between the ED and the control group reported in the present study.
We have no precise explanation for the results reported here, in frank contrast with our hypothesis. However, it is possible that the circulating MMPs and TIMPs levels in ED patients may not reflect tissue-specific expression of MMPs and TIMPs, as previously suggested. 31 In addition, there is evidence that MMP-9 decreases and MMP-2, TIMP-2 and TIMP-2 increase with age. 32 Therefore, it is possible that these MMPs and TIMPs changes with age may obscure MMPs and TIMPs changes associated with ED. However, the subjects included in each study group had similar ages in the present study.
In order to explore any possible relationship between clinical data (IIEF scores) and MMPs or TIMPs levels, we calculated the Spearman's correlation (rs) between IIEF scores and these biochemical parameters. While we found no significant relationships for most variables, we found a negative, significant relationship between IIEF scores and TIMP-1 levels (rs ¼ 0.4435; Po0.001). This negative association is possibly explained by inhibitory effects exerted by TIMP-1 on angiogenic responses, as previously shown. 33 However, this hypothesis remains to be proved.
This study has some limitations. First, patients in the ED/DM group were being treated for DM, and it is possible that the drugs used in the therapy of DM might affect MMPs or TIMPs levels. Curiously, much higher MMP-9 levels were reported in DM patients compared with controls, 19 whereas we found no differences in the present study when the ED/DM group was compared with the control group. While the duration of DM was significantly lower in this previous study, which included both man and women, 19 we are not sure about the precise reasons for such differences between studies. Further studies, possibly including another control group of DM patients without ED, will be required to clarify this issue. Second, some patients in the ED and in the ED/DM groups had hypertension and were receiving antihypertensive drugs. It should be clear that hypertension may increase MMPs levels, as previously shown, 27, 34, 35 and antihypertensive drugs may decrease both MMPs levels and activity. 27 However, it would be unethical to withdraw their treatments and expose them to complications just for the sake of this study. Third, we have studied a relatively small number of subjects. However, the study groups were very similar with respect to many factors that may affect MMPs and TIMPs levels, including age and other disease conditions.
In conclusion, we found evidence indicating lack of significant alterations in circulating net MMP-9 and MMP-2 activities in patients with ED, although we found slightly higher TIMP-1 levels in diabetic ED patients. Whereas our findings are consistent with the idea that MMPs are not major players in the pathogenesis of ED, our results do not rule out a possible role for other MMPs in ED. Moreover, MMPs and TIMPs should be investigated in corpus cavernosum biopsies to examine if the circulating MMPs and TIMPs levels are reflective of tissue MMPs/TIMPs levels. As vascular cells produce MMPs and TIMPs, these findings may open a new area of exploration for ED research.
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